Digital PCR (dPCR) and Real-Time PCR (qPCR) Market by Technology [Digital PCR (dPCR) and Real-Time PCR (qPCR)], Offering [Instruments, Reagents, Software and Services], Application [Clinical Application, Research Application and Forensic Application], End User [Hospitals, Academic Institutes & Research Centers and Diagnostic Centers] – Global Outlook & Forecast 2021-2031
According to the deep-dive market assessment study conducted by Growth+ Reports, the global digital PCR (dPCR) and real-time PCR (qPCR) market was pegged at ~US$ 4.48 billion in 2020. The market is expected to witness a CAGR of ~9.0% from 2021 to 2031.
Rising prevalence of chronic diseases globally, the launch of technologically advanced systems & kits, and increasing use of biomarker profiling for disease diagnostics are some of the pivotal factors propelling the growth of digital PCR (dPCR) and real-time PCR (qPCR) market. However, high cost, false results, and shortage of kits & reagents owing to rising demand for COVID-19 testing are likely to restrain the market growth to a certain extent.
Government bodies and numerous organizations across the globe are implementing several initiatives to fast-track the development of PCR for COVID-19 testing by providing the necessary funding, grants, permissions, clearances & approvals to meet the needs of the healthcare sector. For instance, in Oct 2020, Centogene N.V. announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for ‘CentoSure’, the company’s latest SARS-CoV-2 RT-PCR test. The EUA permits the usage of this test for individuals without any symptoms or suspicion of COVID-19, supporting widespread testing for the global population.
PCR tests allows for rapid and highly specific diagnosis of infectious diseases, including those caused by bacteria or viruses. PCR-based tests are also used to study cancer forming mutations, and customize the therapy regimens to a patient. PCR permits early diagnosis of malignant diseases such as leukemia and lymphomas. According to American Cancer Society’s 2020 estimate, around 60,530 new cases of leukemia (all kinds) and 23,100 deaths from leukemia (all kinds) were recorded in the United States. Therefore, the rising prevalence of infectious diseases and genetic diseases is anticipated to boost the market growth.
In an effort to maintain their position in market, prominent players are continuously launching several novel, compact and portable systems & test kits that can be used for broader range of applications and offer more advantages. For instance, in Dec 2020, Eurofins Technologies announced the launch of a SARS-CoV-2 RT-PCR test to support the fight against COVID-19. It has been successfully validated for pharynx gargling samples, providing a gold standard PCR test in an easy-to-use, self-sampling format especially beneficial in the testing of children.
However, false results associated with the tests is expected to impede its widespread adoption to a certain extent. A false positive result during COVID-19 pandemic may erroneously label a person infected, with consequences including unnecessary quarantine and contact tracing. Whereas, false negative results can be more consequential, as infected persons, who might be asymptomatic, may not be isolated and can infect others.
The Asia Pacific region is projected to be the fastest-growing digital PCR (dPCR) and real-time PCR (qPCR) market. The high growth of the region can mainly be attributed to increasing prevalence of acute & chronic diseases, developing healthcare infrastructure, rising pharmaceutical & life science research activities, and high clinical unmet needs. Countries such as India, China, and Japan in the APAC region, are projected to offer significant growth opportunities owing to the rising geriatric population and increasing cases of COVID-19 in the region coupled with higher usage of PCR in disease diagnosis.
Some of the prominent players operating in the digital PCR (dPCR) and real-time PCR (qPCR) market are Merck KGaA, Thermo Fisher Scientific, Abbott Laboratories, F. Hoffmann-La Roche Ltd, BD, Agilent Technologies, Inc, bioMérieux SA, Danaher, Bio-Rad Laboratories, Inc., QIAGEN, among others.